What is Virun?
Virun operates at the intersection of advanced bioscience and consumer health, specializing in the development of highly bioavailable formulations. The company distinguishes itself through a comprehensive service model that encompasses product formulation, large-scale manufacturing, and co-packing solutions. With a portfolio bolstered by over 100 patents, Virun provides essential infrastructure for brands seeking to deliver USDA-certified organic, non-GMO, and all-natural health products. Their market position is defined by a commitment to technical excellence and a scalable, one-stop-shop approach that addresses the complex production requirements of modern supplement and pharmaceutical enterprises.
How much funding has Virun raised?
Virun has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Virun
PPP
Public-Private Partnership
What's next for Virun?
With the recent influx of capital, Virun is poised to transition into a phase of aggressive market penetration and technological refinement. The strategic focus will likely center on scaling its proprietary formulation platforms to meet the surging demand for clean-label, high-efficacy health products. By optimizing its manufacturing and co-packing efficiencies, the firm aims to solidify its role as a critical partner for global brands navigating the evolving regulatory and consumer-preference landscape. Future growth will be driven by the continued commercialization of its patent-protected technologies and the expansion of its manufacturing capacity to support long-term industrial partnerships.
See full Virun company page
